Evidence map›Paper›PMID 32488882›Full record

ArticleJournal of clinical laboratory analysis2020

Effects of Xeroderma pigmentosum group C polymorphism on the likelihood of prostate cancer.

Yidan Yan, Jianmin Xu, Bin Xu, Qiaxian Wen, Jing Zhou, Lifeng Zhang, Li Zuo, Guoqiang Lv, Yunfeng Shi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yidan YanDepartment of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Jianmin XuDepartment of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China.
Bin XuDepartment of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Qiaxian WenDepartment of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Jing ZhouDepartment of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Lifeng ZhangDepartment of Urology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.ORCID https://orcid.org/0000-0003-2236-9936
Li ZuoDepartment of Urology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.ORCID https://orcid.org/0000-0002-8352-7056
Guoqiang LvDepartment of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China.
Yunfeng ShiDepartment of Urology, Wujin Hospital Affiliated Jiangsu University, Changzhou, China.
Jiangnan University · CNChangzhou No.2 People's Hospital · CNJiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNumerous studies have assessed the association between xeroderma pigmentosum complementation group C (XPC) polymorphisms and susceptibility of prostate cancer (PCa); however, the findings remain inconsistent.

methodsWe performed an updated analysis utilizing data from electronic databases to obtain a more accurate estimation of the relationship between XPC rs2228001 A/C polymorphism and PCa risk. We further used in silico tools to investigate this correlation.

resultsTotally, 5,305 PCa cases and 6,499 control subjects were evaluated. When all studies pooled together, we detected no positive result (recessive genetic model: OR = 1.14, 95% CI = 0.93-1.40, P

conclusionsThe present study indicated that the XPC rs2228001 A/C variant may be associated with elevated PCa risk in Asian patients.

Indexed as

Prostatic NeoplasmsCase-Control StudiesDNA-Binding ProteinsGenetic Predisposition to DiseaseHumansMalePolymorphism, Single NucleotideDNA-Binding ProteinsXPC protein, humananalysisprostate cancervariantXPC

Identifiers

PMID32488882
PMCPMC7521337
OpenAlexW3029134271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.